These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38644056)

  • 21. The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury.
    Earle CM; Keogh EJ; Ker JK; Cherry DJ; Tulloch AG; Lord DJ
    Paraplegia; 1992 Apr; 30(4):273-6. PubMed ID: 1625897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
    Engel JD; McVary KT
    Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Percutaneous use of vasoactive drugs in the diagnosis and treatment of erectile impotence].
    Pastorini S; Marino G; Cocimano V; Marten Perolino R
    Minerva Urol Nefrol; 1992; 44(3):191-3. PubMed ID: 1492270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New developments in self-injection therapy for erectile dysfunction.
    Gingell JC
    Br J Urol; 1998 Apr; 81(4):599-603. PubMed ID: 9598634
    [No Abstract]   [Full Text] [Related]  

  • 25. Erectile dysfunction: a global review of intracavernosal injectables.
    Duncan C; Omran GJ; Teh J; Davis NF; Bolton DM; Lawrentschuk N
    World J Urol; 2019 Jun; 37(6):1007-1014. PubMed ID: 30895359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status of intracavernosal injection therapy in erectile dysfunction.
    Elena BW; Zachary M; Haritha P; Graham BA; Wayne HJG
    Expert Opin Pharmacother; 2023 Jun; 24(8):925-933. PubMed ID: 37078428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunction.
    Lammers PI; Rubio-Aurioles E; Castell R; Castaneda J; Ponce de Leon R; Hurley D; Lipezker M; Loehr LA; Lowrey F
    Int J Impot Res; 2002 Feb; 14(1):54-9; discussion 60. PubMed ID: 11896479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The change of penile blood thromboxane B2 and prostacyclin after intracavernous injection of vasoactive drugs for the treatment of arteriogenic impotence.
    Lin JS; Chang WC; Lui SM
    Proc Natl Sci Counc Repub China B; 1994 Jan; 18(1):12-6. PubMed ID: 8029369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy.
    Raina R; Lakin MM; Agarwal A; Ausmundson S; Montague DK; Zippe CD
    Urology; 2004 Mar; 63(3):532-7; discussion 538. PubMed ID: 15028452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erectile dysfunction: intracavernous treatment.
    Ledda A
    Curr Med Res Opin; 2000; 16 Suppl 1():s59-62. PubMed ID: 11329824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men.
    Richter S; Vardi Y; Ringel A; Shalev M; Nissenkorn I
    Int J Impot Res; 2001 Jun; 13(3):172-5. PubMed ID: 11525316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erectile dysfunction.
    McMahon CG
    Med J Aust; 2000 Nov; 173(9):492-7. PubMed ID: 11149308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience with triple-drug therapy in a pharmacological erection program.
    Govier FE; McClure RD; Weissman RM; Gibbons RP; Pritchett TR; Kramer-Levien D
    J Urol; 1993 Dec; 150(6):1822-4. PubMed ID: 8230514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
    Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
    J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
    Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J
    Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short term use of intracavernous vasoactive drugs in the treatment of persistent psychogenic erectile dysfunction.
    Ghanem H; Sherif T; Adbel-Gawad T; Asaad T
    Int J Impot Res; 1998 Dec; 10(4):211-4. PubMed ID: 9884916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances.
    Moemen MN; Hamed HA; Kamel II; Shamloul RM; Ghanem HM
    Int J Impot Res; 2004 Apr; 16(2):143-5. PubMed ID: 15014552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-year outcome of a progressive treatment program for erectile dysfunction with intracavernous injections of vasoactive drugs.
    Baniel J; Israilov S; Engelstein D; Shmueli J; Segenreich E; Livne PM
    Urology; 2000 Oct; 56(4):647-52. PubMed ID: 11018623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmaco-erection in erectile deficiency after surgical therapy].
    Favre M; Enria T
    Arch Ital Urol Androl; 1999 Sep; 71(4):253-5. PubMed ID: 10592542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intracavernous infusion of drugs].
    Bellorofonte C; Dell'Acqua S; Ruoppolo M; Zaatar C; Tombolini P
    Arch Ital Urol Nefrol Androl; 1992 Sep; 64(3):251-4. PubMed ID: 1439852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.